Nosocomial pneumonia Infections and Infestations Pneumonia
Conditions
Interventions
100 Patients were treated with cefepime and amikacin fixed-dose combination (FDC) 2.5 g twice a day (bid) and 100 patients received cefepime 2 g bid for 7-10 days
Sponsors
Venus Remedies Limited (India)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants included were 200 patients infected with nosocomial pneumonia showing presence of pus cells more than 25 high power fields (HPF) and buccal epithelial cells less than 10 HPF
Exclusion criteria
Exclusion criteria: 1. Hypersensitivity to cefepime, amikacin or related drugs 2. Children or adolescents less than 18 years of age 3. Pregnant women 4. Patients with renal or hepatic insufficiency 5. Patients not willing to give written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome of therapy was based on clinical evaluation and bacteriological evaluation. Bacteriological evaluation was in terms of presence or absence of bacteria in sputum. | — |
Secondary
| Measure | Time frame |
|---|---|
| The cure rate was 65% in the cefepime and amikacin FDC group while clinical improvement was noticed in 24% of the patients. In the group treated with cefepime alone, the cure rate was 44%, while 27% showed clinical improvement. Mild adverse reactions were noticed in both groups. | — |
Countries
India
Outcome results
None listed